


> Trials. 2020 Jun 26;21(1):579. doi: 10.1186/s13063-020-04515-8.

FULL TEXT LINKS

Read free full text at BMC




ACTIONS

Cite

Favorites

SHARE



PAGE NAVIGATION

< Title & authors

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Associated data

Related information

Grant support

LinkOut - more resources

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Alessio Crippa ¹, Bram De Laere ^{2 3}, Andrea Discacciati ², Berit Larsson ², Jason T Connor ^{4 5}, Erin E Gabriel ², Camilla Thellenberg ⁶, Elin Jänes ⁷, Gunilla Enblad ⁸, Anders Ullen ⁹, Marie Hjälml-Eriksson ¹⁰, Jan Oldenborg ¹¹, Piet Ost ¹², Johan Lindberg ², Martin Eklund ², Henrik Grönberg ²

Affiliations + expand

PMID: 32586393 PMCID: PMC7318749 DOI: 10.1186/s13063-020-04515-8

Free PMC article

Abstract

Background: Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular biomarkers have been identified for mCRPC that may have predictive potential to guide treatment selection and prolong PFS. We designed a platform trial to test this hypothesis.

Methods: The Prostate-Biomarker (ProBio) study is a multi-center, outcome-adaptive, multi-arm, biomarker-driven platform trial for tailoring treatment decisions for men with mCRPC. Treatment decisions in the experimental arms are based on biomarker signatures defined as mutations in certain genes/pathways suggested in the scientific literature to be important for treatment response in mCRPC. The biomarker signatures are determined by targeted sequencing of circulating tumor and germline DNA using a panel specifically designed for mCRPC.

Discussion: Patients are stratified based on the sequencing results and randomized to either current clinical practice (control), where the treating physician decides treatment, or to molecularly driven treatment selection based on the biomarker profile. Outcome-adaptive randomization is implemented to early identify promising treatments for a biomarker signature. Biomarker signature-treatment combinations graduate from the platform when they demonstrate 85% probability of improving PFS compared to the control arm. Graduated combinations are further evaluated in a seamless confirmatory trial with fixed randomization. The platform design allows for new drugs and biomarkers to be introduced in the study.

Conclusions: The ProBio design allows promising treatment-biomarker combinations to quickly graduate from the platform and be confirmed for rapid implementation in clinical care.

Trial registration: ClinicalTrials.gov Identifier NCT03903835. Date of registration: April 4, 2019.

Status: Recruiting.

Keywords: Clinical trial platform; Genetic biomarker; Precision medicine; Prostate cancer.

Conflict of interest statement

Henrik Grönberg has received honoraria for giving talks at Janssen, Bayer, and Astellas. All other authors declare no conflict of interest.

Figures



Similar articles

[Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.](#)

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.

PMID: 29673712 Review.

[The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer.](#)

van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B.

Eur Urol Focus. 2016 Dec;2(5):480-487. doi: 10.1016/j.euf.2016.12.006. Epub 2017 Jan 6.

PMID: 28723513 Review.

[Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.](#)

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.

Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.

PMID: 29439820 Free PMC article.

[Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.](#)

Lorente D, Ravi P, Mehra N, Pezaro C, Omlin A, Gilman A, Miranda M, Rescigno P, Kolinsky M, Porta N, Bianchini D, Tunari N, Perez R, Mateo J, Payne H, Terstappen L, IJzerman M, Hall E, de Bono J.

Eur Urol Focus. 2018 Mar;4(2):235-244. doi: 10.1016/j.euf.2016.09.005. Epub 2016 Oct 10.

PMID: 28753792

[Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.](#)

Annala M, Struss WJ, Warner EW, Beja K, Vandekerckhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.

Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.

PMID: 28259476

Show more similar articles

See all similar articles

Cited by 1 article

[AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy.](#)

Winther MD, Kristensen G, Stroomberg HV, Berg KD, Toft BG, Brooks JD, Brasso K, Røder MA.

Diagnostics (Basel). 2020 Jul 27;10(8):520. doi: 10.3390/diagnostics10080520.

PMID: 32726925 Free PMC article.

References

1. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75(1):88-99. - PubMed

2. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630-642. - PubMed

3. Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics. Eur Urol. 2017;71(2):237-246. - PMC - PubMed

4. Tan DSW, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009;15(5):406-420. - PubMed

5. Simon R. Biomarker based clinical trial design. Chin Clin Oncol. 2014;3(3):8. - PubMed

Show all 58 references

Associated data

> ClinicalTrials.gov/NCT03903835

Related information

MedGen

Grant support

4-2689-2016/Familjen Erling-Perssons Stiftelse

09-0677/Cancerfonden (SE)

2017-00413/Svenska Forskningsrådet Formas

LinkOut - more resources

Full Text Sources

BioMed Central

Europe PubMed Central

PubMed Central

Medical

ClinicalTrials.gov

Miscellaneous

NCI CPTAC Assay Portal

Support Center